Cognition Therapeutics (CGTX) Total Current Liabilities (2020 - 2026)
Cognition Therapeutics (CGTX) reported Total Current Liabilities of $6.1 million for Q1 2026, down 44.72% year-over-year from $11.0 million in Q1 2025, and down 56.53% on a QoQ basis from $13.9 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Total Current Liabilities data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 44.72% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 44.72% YoY) and the FY2025 annual result came in at $13.9 million, up 24.97% from the prior year.
- Total Current Liabilities retreated to $6.1 million in Q1 2026 per CGTX's latest filing, from $13.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $13.9 million in Q4 2025 and bottomed at $6.1 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $9.5 million (2024), against an average of $9.6 million.
- The widest annual swing landed in 2022, when Total Current Liabilities surged 173.62%; it then tumbled 47.63% in 2025.
- Tracing CGTX's Total Current Liabilities over 5 years: stood at $7.8 million in 2022, then surged by 30.46% to $10.2 million in 2023, then gained by 9.57% to $11.1 million in 2024, then gained by 24.97% to $13.9 million in 2025, then plunged by 56.53% to $6.1 million in 2026.
- Per Business Quant, the three latest CGTX Total Current Liabilities figures stand at $6.1 million (Q1 2026), $13.9 million (Q4 2025), and $6.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | 6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 13.92 Mn |
| Sep 30, 2025 | 6.65 Mn |
| Jun 30, 2025 | 12.36 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 12.71 Mn |
| Jun 30, 2024 | 10.92 Mn |
| Mar 31, 2024 | 9.50 Mn |
| Dec 31, 2023 | 10.17 Mn |
| Sep 30, 2023 | 8.23 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 7.47 Mn |
| Dec 31, 2022 | 7.80 Mn |
| Sep 30, 2022 | 12.12 Mn |
| Jun 30, 2022 | 6.82 Mn |
| Mar 31, 2022 | 7.65 Mn |
| Dec 31, 2021 | 7.86 Mn |
| Sep 30, 2021 | 4.43 Mn |
| Dec 31, 2020 | 3.25 Mn |